Year: 2026
Type: article
Abstract: Docusate sodium is a widely used stool-softening agent commonly prescribed for the prevention and treatment of constipation. Unlike many medications approved through the U.S. Food and Drug Administration’s New Drug Application process, docusate was incorporated into the over-the-counter laxative monograph in 1975 based largely on historical use rather than robust clinical evidence. As an anionic surfactant laxative, docusate is believed to soften stool by lowering surface tension at the oil–water interface, facilitating the penetration of water and lipids into fecal matter. It is available in oral, rectal, and liquid formulations and is marketed primarily as docusate sodium or docusate calcium. Pharmacokinetically, docusate exhibits minimal systemic absorption and acts mainly within the gastrointestinal tract, contributing to its favorable safety profile. Its onset of action ranges from 6–72 hours when administered orally and 2–15 minutes when given rectally. Despite its widespread use, accumulating evidence indicates that docusate provides limited clinical benefit for relieving constipation, with multiple studies demonstrating little to no superiority over placebo in improving bowel movement frequency or stool passage. While it may offer some benefit in select populations where straining should be avoided, its overall effectiveness in the general constipated population remains questionable. Docusate is generally well tolerated, with mild gastrointestinal adverse effects reported infrequently. However, prolonged or inappropriate use may lead to laxative dependence, electrolyte imbalance, and unnecessary polypharmacy. Additional safety concerns include rare contamination-related infections and formulation-specific risks in vulnerable populations. In conclusion, although docusate sodium remains commonly prescribed, current evidence suggests its clinical efficacy is modest and inconsistent. Reassessment of its routine use is warranted, with consideration of alternative, evidence-based therapies to improve constipation management and patient outcomes.
Source: The Pharma Innovation
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7204110107